Total Funding
83
38
Total FundingSeries A raised
Growth Score
-9 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
39467
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.
- Benjamin Hadida: CEO & Co-Founder
About the Company
Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.
Exeliom develops a
new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.
The company was founded in 2016 and is headquartered in Dijon, France.
